Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001873 · ClinicalTrials.gov registry record · Phase 2
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
A Phase 2 study of Multiple Myeloma and Chronic Lymphocytic Leukemia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT00001873 is a Phase 2 study of Multiple Myeloma and Chronic Lymphocytic Leukemia that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 102 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00001873, a Phase 2 study of Multiple Myeloma and Chronic Lymphocytic Leukemia, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
Cancers of the blood, sometimes referred to as hematologic malignancies, are disorders of bone marrow cells that lead to the failure of the normal function of bone marrow and the uncontrolled growth of cancerous cells in the bone marrow. These cancerous cells can spill over into the bloodstream and affect other organs causing widespread symptoms. The disease is life threatening because it blocks the normal function of the marrow, which is to produce red cells (preventing anemia), white cells (preventing infection), and platelets (preventing progression). Bone marrow transplants are a potential form of therapy for patients with hematologic malignancies. However, BMT is a complicated procedure and can be associated with dangerous side effects. In this study researchers are attempting to find ways to reduce the complications of BMT, so that it would be possible to use it more safely and can be offered more patients. In order to do this, researchers are developing new techniques to make BMT safer. It requires making small changes to the standard procedure, which may improve the outcome. The experimental procedures researchers are evaluating are: 1. \<TAB\>T-cell depleted peripheral blood progenitor cell (PBPC) transplantation 2. \<TAB\> Cyclosporine given immediately after the transplant 3. \<TAB\>Add-back of donor lymphocytes Patients undergoing these experimental techniques must be monitored closely to see if any benefit or harmful effects will occur. Information gathered from this study can be used to develop further research studies and potential new therapies for hematologic malignancies.
Conditions Studied
Interventions
- DEVICE Isolex 300i plus MoAbs
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 1999-02-22 |
| Est. Completion | 2017-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001873
The ClinicalTrials.gov registry entry for NCT00001873 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Isolex 300i plus MoAbs is the first listed.
NCT00001873 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001873 about?
NCT00001873 is a clinical study titled "The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers". Cancers of the blood, sometimes referred to as hematologic malignancies, are disorders of bone marrow cells that lead to the failure of the normal function of bone marrow and the uncontrolled growth of cancerous cells in the bone marrow. These cancerous cells can spill over into the bloodstream and ...
What is the current status of trial NCT00001873?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 1999-02-22. Estimated completion is 2017-06-13.
What conditions does trial NCT00001873 study?
This clinical trial studies the following conditions: Multiple Myeloma, Chronic Lymphocytic Leukemia, Myelodysplastic Syndrome, Graft Vs Host Disease, Hematologic Neoplasm.
What interventions are being tested in trial NCT00001873?
The interventions under investigation include: Isolex 300i plus MoAbs (DEVICE).
Who is sponsoring clinical trial NCT00001873?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001873 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.